{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:04Z","timestamp":1787020084167,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"im health science llc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A randomized, placebo-controlled clinical trial (FDREST) of a novel formulation of caraway oil and L-menthol (COLM-SST) demonstrated symptom relief in patients with functional dyspepsia (FD). Two follow-up studies were conducted to evaluate patient satisfaction, self-regulated dosing, and long-term safety data: FDACT, Functional Dyspepsia Adherence and Compliance Trial, and FDSU36, Functional Dyspepsia Safety Update at 36\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A patient reported outcomes (PRO) questionnaire was designed and distributed online to assess real-world satisfaction and dosing frequency of open-label COLM-SST in patients with FD. A separate study analyzing voluntary safety surveillance data evaluated the frequency and severity of reported adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 600 FD patients were enrolled in the PRO study. Ninety five percent of respondents reported a major or moderate improvement in their FD symptoms and 91.7% indicated a major or moderate improvement in quality of life (QOL) using COLM-SST. Between 1 and 4 capsules were consumed daily by 91.2% of respondents, with 56.2% taking them before meals. Symptom relief was rapid, with 86.4% of respondents indicating relief within 2\u00a0h of taking COLM-SST. Few adverse events (AEs) were reported (0.0187%) by patients using COLM-SST. No serious AEs were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COLM-SST is safe, well tolerated, and provides rapid relief of FD symptoms. These findings, demonstrated in the FDREST trial, were further supported by a large prospective PRO study evaluating self-regulated dosing frequency, symptom improvement, and QOL. COLM-SST was well-tolerated based on review of AE data at 36\u00a0months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02181-5","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:06:57Z","timestamp":1646629617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia"],"prefix":"10.1186","volume":"22","author":[{"given":"Brian E.","family":"Lacy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Chey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Corsino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-2018","authenticated-orcid":false,"given":"Linda R.","family":"Zeitzoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"3","key":"2181_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5056\/jnm20026","volume":"26","author":"YS Kim","year":"2020","unstructured":"Kim YS, Kim N. Functional dyspepsia: a narrative review with a focus on sex-gender differences. J Neurogastroenterol Motil. 2020;26(3):322\u201334. https:\/\/doi.org\/10.5056\/jnm20026.","journal-title":"J Neurogastroenterol Motil"},{"issue":"1","key":"2181_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","volume":"160","author":"AD Sperber","year":"2021","unstructured":"Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders: results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. https:\/\/doi.org\/10.1053\/j.gastro.2020.04.014.","journal-title":"Gastroenterology"},{"issue":"10263","key":"2181_CR3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0140-6736(20)30469-4","volume":"396","author":"AC Ford","year":"2020","unstructured":"Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet. 2020;396(10263):1689\u2013702. https:\/\/doi.org\/10.1016\/S0140-6736(20)30469-4.","journal-title":"Lancet"},{"issue":"1","key":"2181_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/00001574-200411000-00007","volume":"8","author":"TA Voiosu","year":"2013","unstructured":"Voiosu TA, Giurcan R, Voiosu AM, Voiosu MR. Functional dyspepsia today. Maedica J Clin Med. 2013;8(1):68\u201374. https:\/\/doi.org\/10.1097\/00001574-200411000-00007.","journal-title":"Maedica J Clin Med"},{"issue":"12","key":"2181_CR5","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3748\/wjg.v12.i17.2661","volume":"7","author":"S Mahadeva","year":"2006","unstructured":"Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006;7(12):2661\u20136. https:\/\/doi.org\/10.3748\/wjg.v12.i17.2661.","journal-title":"World J Gastroenterol"},{"issue":"19","key":"2181_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMra1501505","volume":"373","author":"NJ Talley","year":"2015","unstructured":"Talley NJ, Ford A. Functional dyspepsia. N Engl J Med. 2015;373(19):1853\u201363. https:\/\/doi.org\/10.1056\/NEJMra1501505.","journal-title":"N Engl J Med"},{"issue":"6","key":"2181_CR7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","volume":"150","author":"V Stanghellini","year":"2016","unstructured":"Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380\u201392. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.011.","journal-title":"Gastroenterology"},{"issue":"11","key":"2181_CR8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/gut.2007.137125","volume":"57","author":"R Bisschops","year":"2008","unstructured":"Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut. 2008;57(11):1495\u2013503. https:\/\/doi.org\/10.1136\/gut.2007.137125.","journal-title":"Gut"},{"issue":"1","key":"2181_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000243783","volume":"81","author":"LB Olafsdottir","year":"2010","unstructured":"Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Thjodleifsson B. Natural history of functional dyspepsia: a 10-year population-based study. Digestion. 2010;81(1):53\u201361. https:\/\/doi.org\/10.1159\/000243783.","journal-title":"Digestion"},{"key":"2181_CR10","unstructured":"Rome IV: functional gastrointestinal disorders, disorders of gut\u2013brain interaction, 4th edn. 2016."},{"issue":"6","key":"2181_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MOG.0000000000000393","volume":"33","author":"J Tack","year":"2017","unstructured":"Tack J, Carbone F. Functional dyspepsia and gastroparesis. Curr Opin Gastroenterol. 2017;33(6):446\u201354. https:\/\/doi.org\/10.1097\/MOG.0000000000000393.","journal-title":"Curr Opin Gastroenterol"},{"key":"2181_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/gutjnl-2019-318536","volume":"69","author":"L Wauters","year":"2019","unstructured":"Wauters L, Talley NJ, Walker MM, Tack J, Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2019;69:591\u2013600. https:\/\/doi.org\/10.1136\/gutjnl-2019-318536.","journal-title":"Gut"},{"issue":"1","key":"2181_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ajg.2016.499","volume":"112","author":"H Vanheel","year":"2017","unstructured":"Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological abnormalities in functional dyspepsia subgroups according to the Rome III Criteria. Am J Gastroenterol. 2017;112(1):132\u201340. https:\/\/doi.org\/10.1038\/ajg.2016.499.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2181_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3748\/wjg.v26.i5.456","volume":"26","author":"M Pesce","year":"2020","unstructured":"Pesce M, Cargiolli M, Cassarano S, et al. Diet and functional dyspepsia: clinical correlates and therapeutic perspectives. World J Gastroenterol. 2020;26(8):456\u201365. https:\/\/doi.org\/10.3748\/wjg.v26.i5.456.","journal-title":"World J Gastroenterol"},{"key":"2181_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/apt.12355","volume":"38","author":"BE Lacy","year":"2013","unstructured":"Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Aliment Pharm Ther. 2013;38:170\u20137. https:\/\/doi.org\/10.1111\/apt.12355.","journal-title":"Aliment Pharm Ther"},{"issue":"3","key":"2181_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2036.2012.05128.x","volume":"36","author":"BE Lacy","year":"2012","unstructured":"Lacy BE, Talley NJ, Locke GR III, et al. Current treatment options and management of functional dyspepsia. Aliment Pharm Ther. 2012;36(3):3\u201315. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05128.x.","journal-title":"Aliment Pharm Ther"},{"issue":"2","key":"2181_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41395-018-0258-6","volume":"114","author":"R Pittayanon","year":"2019","unstructured":"Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol. 2019;114(2):233\u201343. https:\/\/doi.org\/10.1038\/s41395-018-0258-6.","journal-title":"Am J Gastroenterol"},{"key":"2181_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1517\/14728214.2015.1009827","volume":"20","author":"AV Zala","year":"2015","unstructured":"Zala AV, Walker MM, Talley NJ. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2015;20:221\u201333.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"2181_CR19","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s10620-017-4633-8","volume":"62","author":"K Bielefeldt","year":"2017","unstructured":"Bielefeldt K. From harmful treatment to secondary gain: Adverse event reporting in dyspepsia and gastroparesis. Dig Dis Sci. 2017;62(11):2999\u20133013. https:\/\/doi.org\/10.1007\/s10620-017-4633-8.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"e13617","DOI":"10.1111\/nmo.13617","volume":"31","author":"A Al-Saffar","year":"2019","unstructured":"Al-Saffar A, Lennern\u00e4s H, Hellstr\u00f6m PM. Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited. Neurogastroent Motil. 2019;31(11):e13617. https:\/\/doi.org\/10.1111\/nmo.13617.","journal-title":"Neurogastroent Motil"},{"key":"2181_CR21","first-page":"CD011194","volume":"11","author":"MI Pinto-Sanchez","year":"2017","unstructured":"Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11:CD011194.","journal-title":"Cochrane Database Syst Rev"},{"key":"2181_CR22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1046\/j.1365-2036.2000.00873.x","volume":"14","author":"B May","year":"2000","unstructured":"May B, K\u00f6hler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharm Ther. 2000;14:1671\u20137. https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00873.x.","journal-title":"Aliment Pharm Ther"},{"key":"2181_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/nmo.12248","volume":"26","author":"X Sun","year":"2014","unstructured":"Sun X, Ke M, Wang Z, et al. Treatment of functional dyspepsia with enteroplant: a double-blind randomized placebo-controlled pilot phase II clinical trial. Neurogastroent Motil. 2014;26:76.","journal-title":"Neurogastroent Motil"},{"issue":"11","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"e13132","DOI":"10.1111\/nmo.13132","volume":"29","author":"G Rich","year":"2017","unstructured":"Rich G, Shah A, Koloski N, et al. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroent Motil. 2017;29(11):e13132. https:\/\/doi.org\/10.1111\/nmo.13132.","journal-title":"Neurogastroent Motil"},{"issue":"11","key":"2181_CR25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1055\/s-0031-1300528","volume":"49","author":"A Madisch","year":"1999","unstructured":"Madisch A, Heydenreich CJ, Wieland V, Hufnagel R, Hotz J. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study. Arznei-Forschung. 1999;49(11):925\u201332. https:\/\/doi.org\/10.1055\/s-0031-1300528.","journal-title":"Arznei-Forschung"},{"issue":"4","key":"2181_CR26","doi-asserted-by":"publisher","first-page":"e00021","DOI":"10.14309\/ctg.0000000000000021","volume":"10","author":"WD Chey","year":"2019","unstructured":"Chey WD, Lacy BE, Cash BD, Epstein M, Corsino PE, Shah SM. A novel, duodenal-release formulation of a combination of caraway oil and l-menthol for the treatment of functional dyspepsia: A randomized controlled trial. Clin Transl Gastroenterol. 2019;10(4):e00021.","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5056\/jnm18060","volume":"24","author":"H Kyung Jung","year":"2018","unstructured":"Kyung Jung H, Talley NJ. Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift. J Neurogastroenterol. 2018;24(3):345\u201354. https:\/\/doi.org\/10.5056\/jnm18060.","journal-title":"J Neurogastroenterol"},{"issue":"6","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14728222.2020.1752181","volume":"24","author":"L Wauters","year":"2020","unstructured":"Wauters L, Burns G, Ceulemans M, et al. Duodenal inflammation: an emerging target for functional dyspepsia? Expert Opin Ther Targets. 2020;24(6):511\u201323.","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"2181_CR29","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.15191","volume":"49","author":"I Masuy","year":"2019","unstructured":"Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharm Ther. 2019;49(9):1134\u201372. https:\/\/doi.org\/10.1111\/apt.15191.","journal-title":"Aliment Pharm Ther"},{"issue":"10","key":"2181_CR30","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.pain.2013.06.043.TRPM8","volume":"154","author":"B Liu","year":"2013","unstructured":"Liu B, Fan L, Balakrishna S, Sui A, Moris JB, Jordt S-E. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain. 2013;154(10):2169\u201377. https:\/\/doi.org\/10.1016\/j.pain.2013.06.043.TRPM8.","journal-title":"Pain"},{"issue":"37","key":"2181_CR31","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1523\/JNEUROSCI.2221-07.2007","volume":"27","author":"Y Karashima","year":"2007","unstructured":"Karashima Y, Damann N, Prenen J, et al. Bimodal action of menthol on the transient receptor potential channel TRPA1. J Neurosci. 2007;27(37):9874\u201384. https:\/\/doi.org\/10.1523\/JNEUROSCI.2221-07.2007.","journal-title":"J Neurosci"},{"key":"2181_CR32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01421.x","author":"KJ Goerg","year":"2003","unstructured":"Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharm Ther. 2003. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01421.x.","journal-title":"Aliment Pharm Ther"},{"issue":"1","key":"2181_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0086686","volume":"9","author":"AL Rozza","year":"2014","unstructured":"Rozza AL, Meira De Faria F, Souza Brito AR, Udia C, Pellizzon H. The gastroprotective effect of menthol: involvement of anti-apoptotic, antioxidant and anti-Inflammatory activities. PLoS ONE. 2014;9(1):1\u20136. https:\/\/doi.org\/10.1371\/journal.pone.0086686.","journal-title":"PLoS ONE"},{"issue":"7","key":"2181_CR34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3109\/13880200903283681","volume":"48","author":"Q Yu","year":"2010","unstructured":"Yu Q, Li P, Yang Q. Improving the absorption of earthworm fibrinolytic enzymes with mucosal enhancers. Pharm Biol. 2010;48(7):816\u201321. https:\/\/doi.org\/10.3109\/13880200903283681.","journal-title":"Pharm Biol"},{"issue":"3","key":"2181_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cct.2012.02.002.Functional","volume":"33","author":"NJ Talley","year":"2008","unstructured":"Talley NJ, Locke GR III, Herrick LM, et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials. 2008;33(3):523\u201333. https:\/\/doi.org\/10.1016\/j.cct.2012.02.002.Functional.","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"2181_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s10620-018-5343-6","volume":"64","author":"M von Wulffen","year":"2019","unstructured":"von Wulffen M, Talley NJ, Hammer JS, et al. Overlap of irritable bowel syndrome and functional dyspepsia in the clinical setting: Prevalence and risk factors. Dig Dis Sci. 2019;64(2):480\u20136. https:\/\/doi.org\/10.1007\/s10620-018-5343-6.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"2181_CR37","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jama.2018.10136","volume":"320","author":"J Corrigan-Curay","year":"2018","unstructured":"Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867\u20138.","journal-title":"JAMA"},{"issue":"4","key":"2181_CR38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1310\/hpx5204-264","volume":"52","author":"M Gabay","year":"2017","unstructured":"Gabay M. 21st century cures act. Hosp Pharm. 2017;52(4):264\u20135. https:\/\/doi.org\/10.1310\/hpx5204-264.","journal-title":"Hosp Pharm"},{"key":"2181_CR39","unstructured":"U.S. Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices. FDA guidance. 2017. p. 1\u201324. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guida."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02181-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02181-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:16:20Z","timestamp":1646630180000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02181-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02181-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data reported in this study was based on voluntary online participation. Participant names, email addresses or any other identifiable personal information was not collected in conducting the survey. As participation was anonymous, no informed consent was obtained. The study was not submitted to an ethics committee for review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication was not obtained from participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BEL: Scientific advisory boards for Allergan, Salix, IM Health Science, Ironwood, Arena and is a consultant for Viver, Nestl\u00e9 Health Science; WDC: Board member\u2014American College of Gastroenterology, GI on Demand, International Foundation of Functional GI Disorders, Rome Foundation; Consultant\u2014AbbVie, Alfasigma, Allakos, Alnylam, Arena, Bayer, Biomerica, Cosmo, IM Health Science, Ironwood, QOL Medical, Nestl\u00e9 Health Science, Phathom, Redhill, Ritter, Salix\/Valeant, Takeda, Urovant, Vibrant; Grant\/Research Support: Bioamerica, Commonwealth Diagnostics International, QOL Medical, Salix; Stock\/Stock options: GI on Demand, Modify Health; MSE: Consultant to Nestl\u00e9 Health Science; Speaker for BMS, Redhill, Gilead, Salix. Pfizer. SMS: Consultant to Nestl\u00e9 Health Science; PC: none; LRZ: employee Nestl\u00e9 Health Science; BDC: Consultant to Nestl\u00e9 Health Science.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}